Replies to post #127725 on Biotech Values

[DewDiligence]

The TMC435 SVR data in #msg-67609174 are impressive, IMO. The only thing I question in the dataset from the PILLAR study is the relapse of some patients more than six months after the end of treatment, but this is presumably a fluke rather than an indictment of TMC435.